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Introduction
Autophagy is an evolutionarily conserved pathway for the 
turnover of organelles and proteins by lysosomal-dependent 
processing1. During autophagy, newly formed double-membrane 
structures, called autophagosomes, encapsulate cytoplasmic mate-
rial, such as dysfunctional or damaged organelles or proteins. 
The autophagosomes then fuse with lysosomes, thus deliver-
ing the sequestered cargo for lysosomal-dependent degradation2, 
as described in Figure 1. In the last decade, autophagy has 
emerged as a fundamental process involved in tissue and cellular 
homeostasis, and thus has been implicated in maintaining basal 
physiologic (healthy) and adaptive pathophysiologic responses 
(disease)2–4. There is increasing evidence to suggest that 
autophagy can impact the pathogenesis and/or progression of 
many human diseases2,4,5, including neurodegenerative diseases6, 
cancer7, heart diseases8,9 and immune disorders (reviewed in 3,10).
Fibrotic airway remodeling remains a key pathological feature 
correlating with a decline in lung function and disease 
progression in both asthma and chronic obstructive pulmonary 
disease (COPD) patients11–13. While there is no treatment for 
preventing development of airway remodeling, cell fate phenom-
ena, such as autophagy, have been shown to play a role in asthma 
and COPD pathogenesis. Here, we review the progress in under-
standing how autophagy can contribute to airway fibrosis and the 
emerging strategies to target this process for therapeutic benefit.
Evidence of autophagy in asthma
Asthma is a chronic inflammatory disease of the lungs, char-
acterized by airway inflammation, airway hyperresponsiveness 
and tissue remodeling. It affects more than 300 million people 
worldwide and this number is estimated to escalate to 
400 million by 202514.
The role of autophagy in pulmonary diseases has gained atten-
tion in the past decade, but only very few studies have described 
the role of autophagy in asthma. One of the very first studies that 
described a direct role between asthma and autophagy revealed 
the association of the ATG5 gene in the pathogenesis of asthma15. 
This study found a genetic association in 1338 adult patients with 
asthma and the expression of the autophagy gene ATG5. ATG5 
encodes the ATG5 protein of 276 amino acids. During autophagy, 
the ATG5 protein interacts with ATG12 and ATG16 to form 
a ATG12-ATG5-ATG16 complex. This complex is associated with 
autophagosomal membrane elongation by interaction with ATG3, 
leading to ATG8-phosphatidyl ethanolamine formation16. This 
Figure 1. Pictorial representation of the autophagy pathway. The autophagy pathway proceeds through several phases, including 
initiation (formation of a preautophagosomal structure leading to an isolation membrane, or phagophore), vesicle elongation, autophagosome 
maturation and cargo sequestration, and autophagosome–lysosome fusion. In the final stage, autophagosomal contents are degraded by 
lysosomal acid hydrolases and the contents of the autolysosome are released for metabolic recycling.
      Amendments from Version 1
In the revised version we have addressed the comments and 
suggestions made by the reviewers. Particularly we have added 
some text on role of autophagy in EMT and its potential link with 
airway remodeling in COPD. We have modified the Figure 2 and 
have added a link between circadian rhythm and autophagy 
and its potential impact on airway fibrosis. Further we have now 
updated references as suggested by the reviewers. The revised 
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association was further validated in another study with 312 asth-
matic and 246 control children, which showed that genetic 
variants in ATG5 are associated with pathogenesis of childhood 
asthma17,18. Furthermore, a study by Poon et al. revealed the role 
of ATG5 in adult asthma, and also found an increased number 
of autophagosomes in fibroblast and epithelial cells from severe 
asthmatics when compared to healthy volunteers16. Recent stud-
ies show that there is emerging evidence for the role of autophagy 
in both eosinophilic19 and neutrophilic asthma20, and convey its 
link to severe asthma and fibrotic tissue remodeling.
A recent study by Ban et al. investigated the role of autophagy 
in sputum granulocytes, peripheral blood cells and peripheral 
blood eosinophils of severe and non-severe asthmatics21. They 
found increased autophagy in the immune cells from the severe 
asthmatics when compared to non-severe and healthy controls. 
This clearly indicates that induction of autophagy in immune 
cells is associated with severe asthma. By contrast, a study con-
ducted by Akbari’s group reveals the induction of neutrophilic 
airway inflammation and hyperreactivity on deletion of CD11 
cell specific ATG5 mice. In addition, in this study augmented 
neutrophilic inflammation in Atg5(-/-) mice is IL-17A driven and 
glucocorticoid resistant22.
In our own hands, we have found increased signatures of key 
autophagy genes in the lungs of asthmatic patients when com-
pared with non-asthmatics, suggesting that basal autophagy is 
higher in asthma (unpublished data). Furthermore, we also found 
increased expression of autophagy proteins in the lung tissue 
obtained from chronic mouse model of HDM-induced asthma and 
this expression was found to correlate with pro-fibrotic signal-
ing (Smad) and extracellular matrix protein (collagen) in the lung 
(unpublished data).
These data suggest that autophagy and airway fibrosis occur 
together with allergic insult, and act as a key driver for airway 
remodeling in allergic asthma. The current literature clearly indi-
cates that the autophagy-phenomenon may be a crucial driver in 
the pathogenesis of asthma, particularly in severe forms of the 
disease, with an unknown underlying mechanism. The therapeu-
tic modulation of autophagy with novel inhibitors may lead to the 
development of a new class of drugs for severe asthma.
Evidence of autophagy in COPD
COPD is a progressive lung disease characterized by accelerated 
decline in lung function over time. Its most common pathologi-
cal feature includes emphysema and chronic bronchitis. Airway 
obstruction in COPD in associated with formation of peribron-
chial fibrosis, increased wall thickness and excess mucus secre-
tion, especially in the smaller airways23. Exposure to cigarette 
smoke is one major cause of COPD; however only 25% of smok-
ers develop COPD, which suggests the existence of numerous 
other factors contributing to COPD (such as genetic predisposition 
and oxidative stress)24,25. The role of autophagy in COPD seems 
to be more complex than anticipated, as some studies showed 
its impairment26–28, while others suggest it facilitates disease 
pathogenesis29–32. More recently, the role of selective autophagy 
(such as mitophagy, ciliophagy and xenophagy) in COPD 
pathology has been proposed32.
The very first demonstration of autophagy in COPD was shown 
by Chen et al., where authors found increased autophagy markers 
in the lungs of COPD patients29. The authors also found a simi-
lar expression of elevated autophagy markers at various stages of 
the disease. This suggests that altered autophagy could be a key 
regulator in the pathogenesis and progression of COPD. The 
same study also showed that the autophagy marker LC3II/LC3I 
was significantly increased in lungs from patients with α-1 anti-
trypsin deficiency when compared with non-COPD donors29. In 
addition, many other studies have shown the increased expression 
of autophagy markers both in vitro and in vivo when exposed to 
cigarette smoke extract17,29,30,33, which explains increased loss of 
alveolar epithelial cells as seen in emphysema.
Moreover, to investigate the role of autophagy in chronic bronchi-
tis, Lam and colleagues demonstrated that induction of autophagy 
leads to shortening of cilia in mouse tracheal epithelial cells 
exposed to cigarette smoke31. They further found that autophagy 
gene deficient mice (Becn1+/- or Map1lc3B-/-) were resistant to 
the shortening of cilia in tracheal epithelial cells when exposed to 
cigarette smoke, demonstrating a direct role of autophagy in this 
process31. Recent studies have demonstrated that selec-
tive autophagy (namely mitophagy) plays an important role in 
regulating mitochondrial function, which in turn has a cru-
cial role in COPD pathogenesis34. However, the specific role of 
mitophagy in tissue injury mediated by cigarette smoke 
remains obscure and requires further study32.
Overall, autophagy plays a key role in COPD pathogenesis, espe-
cially in the development of emphysema, but the underlying 
mechanisms by which it promotes emphysema and bronchitis in 
COPD is not clear.
Autophagy and fibrotic airway remodeling
The pathogenesis of COPD and asthma is typified by structural 
changes in the lung, collectively known as airway remodeling, 
which is characterized by basement membrane fibrosis, epithelial 
goblet cell hyperplasia, deposition of extracellular matrix proteins 
and smooth muscle hypertrophy35,36. Current therapies provide 
very limited benefit on airway remodeling12,37–41, thus identifying 
new drug targets that can prevent or reduce airway remodeling 
in asthma and COPD is vital to reverse structural changes that 
determines the underlying cause of the disease35,42. TGFβ1 is a 
well-known regulator of inflammation and fibrotic remodeling in 
COPD and asthma, and it is upregulated in both diseases11. TGFβ1 
is the most abundant isoform of the TGF-β family and is secreted 
by most immune cells, including airway epithelial, smooth mus-
cle, fibroblast and endothelial cells. TGFβ1 acts through the 
Smad dependent pathway and independent pathways, like mitogen 
activated protein kinases (MAPKs) namely p38 MAPK and 
c-Jun-N-terminal kinase, leading to the accumulation of extracel-
lular matrix (ECM).
Autophagy-mediated TGFβ1-induced fibrosis plays a key role 
in the pathogenesis of heart and kidney diseases43,44, and recent 
studies in human airway smooth muscle cells have demonstrated 
that TGFβ1 induced autophagy is required for collagen and 
fibronectin production, while silencing of key autophagy-inducing 
proteins Atg5 and Atg7 leads to reduction in pro-fibrotic signaling 
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and ECM protein release45,46. It is now believed that increased 
production of matrix proteins, as seen in airway remodeling, 
requires huge resources of energy, which is compensated by 
enhanced autophagy flux within the cell46. Our own data (unpub-
lished) demonstrates that there is a simultaneous induction of 
autophagy and pro-fibrotic signaling in human airway mouse 
models of allergic asthma. We propose that blockade of autophagy 
in the lungs can lead to reduction in airway fibrosis, as seen in 
airway remodeling in asthma and COPD. Recent observations 
suggest that autophagy exhibits a circadian rhythm and this 
rhythmic activation of autophagy is regulated by the transcrip-
tion factor C/EBPβ47. These findings need to be further evaluated 
in the context of asthma and COPD, as circadian rhythm genes 
can also be a potential target to modulate autophagy47.
Therapeutic strategies: Novel autophagy modulators
The mechanistic insight of disease pathogenesis in chronic air-
way diseases, such as asthma and COPD, is complex. Altered 
structural changes in the lung correlates with poor lung function, 
severity of disease and response to therapy in asthma and 
COPD. Current therapy does not target the underlying cause/s 
of the disease and does not restore the structural integrity of the 
airways12,37–41; therefore, novel mechanisms, such as autophagy, 
pose attractive therapeutic options in airway remodeling. With 
the emerging role of autophagy in asthma and COPD and our 
increased understanding in the disease pathogenesis, we believe 
that the autophagy pathway can be exploited for therapeutic 
benefit. One of the exciting features of this pathway is that it 
can be inhibited at several steps, including initiation and vesi-
cle elongation, autophagosome formation and maturation, and 
autophagosome lysosome fusion. Emerging evidence suggests that 
autophagy inhibition at the very first step is beneficial in an 
ovalbumin-induced model of asthma in mice, where 3-methyl 
adenine, a class III PI3K inhibitor, reduced the expression of 
autophagy marker LC3B with simultaneous reduction in air-
way eosinophilia19. However, there is a need for more research 
in exploring the role of various PI3K inhibitors in the context of 
autophagy dependent-airway remodeling, using the most suit-
able models of asthma and COPD, as modulation of autophagy 
by the PI3K pathway can be an attractive target for both 
severe asthma and COPD48–51.
Bafilomycin A1 is a late phase potent inhibitor of autophagy, 
which acts through the inhibition of vacuolar type H+-ATPase that 
is present on lysosomes. Inhibition of vacuolar type H+-ATPase 
by bafilomycin A1 leads to acidification of lysosomes and inhibits 
their fusion with autophagosomes52. Previous studies also indi-
cate that bafilomycin inhibits the infection and airway inflam-
mation induced by rhinovirus53. Chloroquine is a well know 
anti-malarial and anti-rheumatoid agent, and it is also used for 
blocking autophagy at a late stage by lysosomal dysfunc-
tion (lysosomal lumen alkalizers)52. The most important short-
coming of chloroquine is that this molecule blocks autophagy 
only at higher concentrations. Lys01 and Lys05 were recently 
developed modified versions of chloroquine, which are 
10-fold more potent in autophagy inhibition52,54,55; however 
these require further validation in asthma and COPD models.
Kinases, such as adenosine monophosphate activated protein 
kinase (AMPK) and ULK1 (mammalian orthologue of yeast 
protein kinase Atg1) are required for autophagy. AMPK senses 
nutrient deficiency and positively regulates ULK1, leading to 
activation of autophagy. Moreover, it has been reported that 
loss of either of these kinases results in defective autophagy 
(mitophagy)56. Modulating the AMPK-ULK1 pathway may be an 
option for treatment of chronic airway diseases. Further recent 
observations suggest that autophagy exhibits a circadian rhythm 
and this rhythmic activation of autophagy is regulated by the 
transcription factor C/EBPβ47. These findings need to be further 
evaluated in the context of asthma and COPD, as circadian 
rhythm genes can also be a potential target to modulate autophagy.
Thus, there is a need to identify the right autophagy mechanism 
in the progression and development of airway remodeling in 
asthma and COPD, which can become a realistic drug target 
to prevent structural changes in the lung.
Conclusions and future perspectives
Based on the current scientific data, the autophagy pathway 
is directly linked to asthma and COPD pathophysiology and 
may act as a potential contributor to fibrotic airway remodeling, 
as described in Figure 2. Future research should be directed 
towards understanding the specific pathway and the mecha-
Figure 2. Autophagy mediates airway remodeling. An altered 
autophagy pathway is seen in response to cellular stress in 
asthma and chronic obstructive pulmonary disease (allergens or 
smoke or genetics), leading to activation and crosstalk between 
structural airway and immune cells. This further leads to impairment 
of autophagy causing degradation of intracellular constituents, 
providing an energy resource for ECM protein biosynthesis, and 
releasing mediators of inflammation and profibrotic signaling, which 
collectively lead to airway remodeling in the lung. Role of circadian 
rhythm genes in this context needs to be investigated. ECM: 
extracellular matrix; TGFβ: transforming growth factor-beta.
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nism/s leading to the pathophysiological activation of autophagy 
in disease. Efforts should be made in developing a modulator of 
autophagy as a new therapeutic strategy for treatment of airway 
remodeling in asthma and COPD. In the future, we propose to study 
the role of circadian rhythm genes in the activation of the autophagy 
pathway and understand whether modulating circadian rhythm 
genes, using novel small chemical compounds, has any 
therapeutic benefit in animal models of asthma and COPD.
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C1: Before authors go into the details for role of autophagy in asthma/remodelling, I think they
need to add a separate section on airway remodelling and autophagy first.
: We have now added this to the text.R1
C2: Please list the airway remodelling changes described in asthma so far and then discuss which
might be related to autophagy.
: We have now added new text to the MS.R2
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might be related to autophagy.
: We have now added new text to the MS.R2
C3: I think authors need to add a reference if there is any work done on fibroblast populations in
.asthma to make the case for fibrosis or suggest as potential future work
We have added references related to fibroblasts and potential future direction in this area.R3: 
C4: Similar changes I think need to be made for the COPD section, especially listing airway
remodelling changes described so far, for example Rbm fragmentation, vascularity, epithelial
mesenchymal transition (EMT) etc.
 We have now modified the text and added these suggestions as well.R4:
C5: Authors stated in the evidence for autophagy in COPD section that major features are
emphysema and chronic bronchitis. I think it is very important to describe small airway destructive
pathology in COPD. The classic fixed airflow obstruction described in COPD comes from the small
airways. These airways are destroyed by up to nearly 40% well before the diagnosis of COPD. So,
damage starts quite early on and it is this site where fibrosis really occurs and EMT is central to
this. Airway disease is the primary phenomenon in COPD.
These are valid points made by the reviewers, we have modified the text in the MS.R5: 
C6: EGFR has also been regarded as one of the important drivers of airway remodeling in asthma
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C1: Figure 2 can be improved. Eg: at the arrow between Autophagy and Cell Growth/ECM release,
the authors can add the words increase energy resource, so the readers understand the
association between Autophagy and Cell Growth/ECM release. Authors should consider adding
‘Genetics’ into the figure. The authors could add ‘circadian rhythm’ into the figure with a ‘?’ to show
that it is a factor for further investigation.
We have modified the figure accordingly.R1: 
C2: For the collectively structural changes of airway remodeling, please include smooth muscle
hyperplasia (James et al. 2012; Am J Respir Crit Care Med).
We have now added this with the reference.     R2: 
C3: In the autophagy and fibrotic airway remodelling section, the paragraphs could be rearranged.
Eg do not split TGFb1 between the paragraphs. The section about circadian rhythm seems to be a
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C3: In the autophagy and fibrotic airway remodelling section, the paragraphs could be rearranged.
Eg do not split TGFb1 between the paragraphs. The section about circadian rhythm seems to be a
better fit in the Therapeutic strategies: Novel autophagy modulators section, as it is something to
further evaluate as a potential target.
It has been moved to the section on novel autophagy modulators.R3: 
C4: Are there any genetic component as evidence of autophagy in COPD? For example: Chen et
al. 2015; J Formos Med Assoc.
Not as far as we know.R4: 
 C5: Should have a reference for the sentence regarding TGFb1 leads to accumulation of ECM.
ECM could be abbreviated earlier in the article
Reference added. R5: 
 NoneCompeting Interests:
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 C1: As stated, this is by no means an easy literature review to compose. At first one would think
this is due to limited publication of such studies. However, a PubMed search using “Fibrosis[Title]
and Autophagy[Title]”, show there are 83 hits for this query. While the vast majority are not
respiratory in nature, it would be beneficial if Kota et al. could use mechanistic insights from other
diseases to draw hypothetical parallels with the situation that may be occurring in the airways,
which they elude to in paragraph 2 under the heading “Autophagy and fibrotic airway remodelling”,
but little supposition is made in regard to this thereafter. Indeed, this paragraph is possibly the only
one which directly address the subject matter stated by the title. Refreshingly however, they
generously state new unpublished finding (on three occasions) from their laboratory which
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generously state new unpublished finding (on three occasions) from their laboratory which









C2. A current question for autophagy is: is it a block in autophagic flux leading to (or contributing to)
the cellular dyshomeostasis, or is autophagy increased because it is unable to manage the
protracted/chronic disease stressors? While Kota et al. touch upon this question for COPD, and
correctly state that there is significant conjecture with regards to this, subsequent discussion
mainly lent to the increased autophagy scenario, with an extended discussion with regards to cilia
(ciliophagy). Indeed, we now know the relationship between cilia and autophagy is a complex dual
interaction whereby they foster each other’s activity/generation rather than a one-way situation
where increased autophagy leads to the degradation of cilia (Pampliega et al., 2016). Hence, some























C4. The manner of composition on occasions lacks maturity. For example, “ATG5 encodes a
protein of 276 amino acids”, is not needed in a review article. The chronological presentation of
concepts/studies, should be forfeited to a style of writing that groups and discusses processes to
illustrate a pattern of phenomena that helps orient/inform the reader. Avoid using definite
statements such as “clearly indicates”, particularly in a review, and especially in areas where we
have so much more to learn such as is the case for chronic lung disease and autophagy. Finally,
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have so much more to learn such as is the case for chronic lung disease and autophagy. Finally,
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